Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10778839 | 0.87 | SMN1; SMN2 (0.52) | TDP1SMN1; SMN2TP53EPHX1TSHR | |
| Hydrochloric Acid SCHEMBL11405284 | 0.84 | SMN1; SMN2 (0.50) | TDP1SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL12973520 | 0.79 | SMN1; SMN2 (0.74) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL11593321 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL28386018 | 0.79 | SMN1; SMN2 (0.61) | TDP1SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL272215 | 0.78 | SMN1; SMN2 (0.67) | TDP1SMN1; SMN2TSHRPOLBMAPT | |
| SCHEMBL2235161 | 0.78 | PEPD (0.64) | MAPTRAB9ANPC1HSD17B10GAA | |
| SCHEMBL6832116 | 0.78 | POLB (0.50) | POLBMAPTRAB9ANPC1 | |
| SCHEMBL612152 | 0.77 | MAOA (0.64) | TP53TSHRMAPTRAB9ANPC1 | |
| SCHEMBL455439 | 0.77 | TDP1 (0.70) | TDP1SMN1; SMN2POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-RE47690-E1 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-02-15 | — | — | US | disclosed |
| US-9840520-B2 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-20170081343-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-03-23 | — | — | US | disclosed |
| EP-3142652-A1 | HETEROCYCLIC HYDROXAMIC ACIDS AS PROTEIN DEACETYLASE INHIBITORS AND DUAL PROTEIN DEACETYLASE-PROTEIN KINASE INHIBITORS AND METHODS OF USE THEREOF | The Regents of the University of Colorado, a body corporate (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| WO-2015175813-A1 | HETEROCYCLIC HYDROXAMIC ACIDS AS PROTEIN DEACETYLASE INHIBITORS AND DUAL PROTEIN DEACETYLASE-PROTEIN KINASE INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-2478361-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | Avila Therapeutics, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011034907-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| EP-2229391-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2009077766-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| WO-2004065369-A1 | CARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
| US-5236944-A | C1-4 alkyl(4-(2-(4-C1-4-alkylphenyl)-2(1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-ylemthlthio)phenyl)carbamate | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-08-17 | — | — | US | disclosed |
| EP-0335446-A2 | Agents for treating neoplasms | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-10-04 | — | — | EP | disclosed |
| US-4490540-A | FUNGICIDES, ANTITUMOR AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-12-25 | — | — | US | disclosed |
| EP-0052905-B1 | NOVEL (2-ARYL-4-PHENYLTHIOALKYL-1,3-DIOXOLAN-2-YL-METHYL)AZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-03 | — | — | EP | disclosed |
| EP-0052905-A1 | Novel (2-aryl-4-phenylthioalkyl-1,3-dioxolan-2-yl-methyl)azole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, ADK, TTK | TDP1 1864/4885SMN1; SMN2 4778/4885TP53 663/4885 |
| US-20170081343-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | TTK, HDAC1, HDAC6 | TDP1 541/4885SMN1; SMN2 2537/4885TP53 2176/4885 |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | TTK, HDAC1, HDAC6 | TDP1 541/4885SMN1; SMN2 2537/4885TP53 2176/4885 |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | CDKN1A, SERPINB1, SPR | TDP1 2753/4885SMN1; SMN2 4842/4885TP53 699/4885 |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | MAP3K20, ADK, TTK | TDP1 1864/4885SMN1; SMN2 4778/4885TP53 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.